#version: 0.2
i n
t i
r e
t h
a n
e n
e r
e d</w>
o n
o f</w>
a t
th e</w>
r o
i n</w>
a ti
i t
an d</w>
a r
o n</w>
s t
s i
a l
a l</w>
o r
i c
a s
e c
d i
a c
en t
l o
in g</w>
t o</w>
o r</w>
u r
e r</w>
a s</w>
a m
e s
c o
w it
u l
wit h</w>
o l
d e
s e
u c
in e</w>
re s
p h
en t</w>
l e
l y</w>
ati on</w>
r i
v e</w>
c on
p ati
w as</w>
p ro
e s</w>
o u
T h
d uc
er e</w>
c h
m e
v e
at ed</w>
s .</w>
i d
f f
r a
o s
o c
i s</w>
a n</w>
p er
i c</w>
u s
a t</w>
ent s</w>
a g
i m
o t
a d
h e
w ere</w>
i l
ti on</w>
s u
a p
u n
co m
c e
p a
duc ed</w>
f or</w>
b e
t re
ec t
n e
i s
Th e</w>
t er
e x
b y</w>
re n
in e
p l
pati ents</w>
a b
v er
r at
e ff
t o
e m
in duced</w>
ati on
it y</w>
h i
d o
in c
h y
w e
th at</w>
e n</w>
p res
s ,</w>
n o
re as
t er</w>
h a
c e</w>
t e
a r</w>
re d</w>
m in
a f
u d
m ent</w>
ti on
g n
l i
con t
u t
m a
r an
s y
- induced</w>
i f
an t
p re
v i
l e</w>
h o
c ar
at e</w>
ti c</w>
af ter</w>
ti ve</w>
c a
w h
p or
y .</w>
tre at
ic al</w>
r u
c l
th er
m o
i st
p o
0 .
si on</w>
b e</w>
q u
on e</w>
si gn
m or
no t</w>
g /
or m
as e</w>
) .</w>
e d
y ,</w>
an t</w>
o m
as s
g h
i z
ro u
p ar
inc reas
d a
u m
p i
eff ect
in f
ul ar</w>
u m</w>
th e
) ,</w>
if ic
m on
e t
os e</w>
e v
y l
ther ap
s er
si s</w>
ur e</w>
in t
re ce
in g
ti v
c or
d ru
s e</w>
f i
lo w
i o
d ur
lo g
I n</w>
th er</w>
g en
sign ific
o x
st ud
m ic
an ti
treat ment</w>
ou s</w>
s ho
oc i
b u
ar e</w>
an g
m g/
en ce</w>
o b
e st
u s</w>
u re
ro m</w>
min ist
v ed</w>
ti c
pa th
l l
effect s</w>
lo p
al ly</w>
ec t</w>
to x
e .</w>
ent r
u ro
f rom</w>
in d
be t
res p
ass oci
p t
ad minist
th is</w>
i a</w>
tre ated</w>
di s
us e</w>
g rou
car di
si on
un c
es e</w>
re l
ha d</w>
de ve
ation s</w>
e l
ul t
e ar
e ,</w>
su b
ac tiv
t en
b lo
hy per
ro m
ren al</w>
ar y</w>
am ine</w>
S :</w>
deve lop
ot en
f ol
e p
w i
re por
dur ing</w>
ve l
ti m
associ ated</w>
th an</w>
stud y</w>
cont ro
+ /
ne uro
us ed</w>
rat s</w>
hi b
d ose</w>
y c
pati ent
d er
am in
ag e</w>
d .</w>
t ran
r on
m ent
y s
r ac
a z
O N
ou n
d e</w>
o log
g h</w>
c ur
wi th
tox ic
bu t</w>
si ve</w>
f unc
ut e</w>
d ec
r ation</w>
eff ect</w>
es t</w>
p os
p en
n orm
ma y</w>
l l</w>
es s</w>
es .</w>
ati ve</w>
1 0
in j
in hib
su g
p oten
se s</w>
ec tive</w>
c i
s p
b o
0. 0
fol low
u di
t ed</w>
be en</w>
sug g
g ra
we e
i d</w>
w he
resp on
o d</w>
c entr
pro te
tran s
ha ve</w>
or y</w>
W e</w>
wh o</w>
mg/ k
me th
v en
dec reas
al u
pres s
an ce</w>
a in
l u
increas ed</w>
an c
sho w
g i
ff e
al l</w>
sy n
+/ -</w>
therap y</w>
st udi
in v
en c
rece i
in ter
da y
re qu
ch ang
id e</w>
ation .</w>
y ear
o l</w>
com p
cl in
ul d</w>
signific ant
res ult
i ti
er g
dru g</w>
administ ration</w>
ri s
i r
i a
al l
v er</w>
s ec
mic ro
Th is</w>
rece pt
ar di
pati ent</w>
ac t
a st
ine -induced</w>
ect ed</w>
ac ute</w>
ou t</w>
le vel
l on
ec h
dru g
ob ser
n o</w>
me di
es ,</w>
d er</w>
a il
ot h</w>
significant ly</w>
m y
ic h</w>
h as</w>
( 1
we en</w>
s en
p e
hi gh
c al
wh ich</w>
f orm
bet ween</w>
a k
ve n</w>
grou p
re e</w>
pa red</w>
ine .</w>
p to
i gh
duc tion</w>
ch em
te st
he ar
ch ol
ab le</w>
th ese</w>
int ra
inhib it
id ence</w>
ed .</w>
t w
t ri
di se
si b
ffe ren
es s
activ ity</w>
ar i
develop ed</w>
al o
wee k
re at
ec tion</w>
b ra
com pared</w>
E S
pl ic
tion .</w>
ti al</w>
signific ant</w>
s o</w>
r am
mor e</w>
g lo
al y
c ase</w>
tion s</w>
norm al</w>
b oth</w>
b l
rat e</w>
l im
di fferen
clin ical</w>
re g
p ri
or s</w>
c as
5 -
1 .
v as
m s</w>
do p
blo od</w>
ag on
show ed</w>
s t</w>
m at
an d
u sion</w>
se iz
ris k</w>
pl as
ph a
oc cur
f or
f ail
oc ardi
co ca
b in
toxic ity</w>
rel ated</w>
it s</w>
i t</w>
i al</w>
grou p</w>
con centr
t s</w>
m a</w>
lon g
ex per
st er
ph en
1 0</w>
lo s
he pati
g l
di d</w>
I ON
ti s</w>
t y
sy m
st r
ou r</w>
mor ph
m il
m al
d ys
ch ron
at ing</w>
al so</w>
( 2
se l
rat s.</w>
ol y
level s</w>
fi r
ou s
o ther</w>
mon th
ev alu
E T
A C
' s</w>
se v
ind ic
follow ing</w>
d ro
contro l</w>
C L
ul ation</w>
oun d</w>
m an
ec ti
sy st
mo de
il e</w>
func tion</w>
f requ
day s</w>
ar ter
Th ese</w>
L T
y m
si de</w>
me t
m un
iz ed</w>
erg ic</w>
e -
de f
whe n</w>
th rom
ol d</w>
le v
ech an
d u
cardi a
U S
% )</w>
ver se</w>
ver ,</w>
tw o</w>
su p
re c
or al</w>
ne ph
lo w</w>
d ic
cont in
c ular</w>
blo c
an e
0 0</w>
st o
path y</w>
mg/k g</w>
m g</w>
m echan
olog ical</w>
increas e</w>
b as
al pha
n it
u se
t ac
obser ved</w>
er s</w>
da y</w>
d am
c ri
at ri
2 .
ure s</w>
treat ment
ti g
si st
il ity</w>
hyper ten
th i
sym pto
on ly</w>
l ess</w>
de ter
chron ic</w>
ar k
result s</w>
re f
os t</w>
me as
m er
ar g
US ION
ON CL
ONCL USION
M ET
H O
C ONCLUSION
si a</w>
prote in
o ph
it y.</w>
ine ,</w>
gen er
d y
cas es</w>
I n
5 0</w>
ver y</w>
v ari
us ing</w>
sugg est</w>
s uc
mechan is
hy poten
ex pos
enc y</w>
sib le</w>
sho uld</w>
s ti
r al</w>
hear t</w>
ed ,</w>
decreas ed</w>
com bin
ation ,</w>
al s</w>
ac et
v ing</w>
re t
es tig
de pen
c y
5 %</w>
tion ,</w>
sev ere</w>
s ur
respon se</w>
press ure</w>
n on
contin u
bloc k
ant agon
ac e
a x
3 .
pa in</w>
o di
inv estig
ca used</w>
w e</w>
u b
re ac
my ocardi
l ud
im mun
contro l
am i
U LT
R ES
RES ULT
2 -
with out</w>
pres ent</w>
neph ro
m i
l at
depen d
ar c
RESULT S:</w>
t h</w>
sugg est
ser um</w>
m ost</w>
inc lud
igh t</w>
f ound</w>
we ver,</w>
t e</w>
studi es</w>
sen si
s h
e th
MET HO
METHO D
u p
tion al</w>
th ou
s al
repor t</w>
re co
oc y
in .</w>
en ce
do ses</w>
th ose</w>
pres sion</w>
p at
i r</w>
glo mer
repor ted</w>
recei ved</w>
pro t
li ver</w>
ine -
ce ll
am ph
ad verse</w>
5 0
sec on
recept or</w>
in -
i .
ha vi
f act
cardia c</w>
re duced</w>
p er</w>
in ,</w>
il l
ic i
f e
chang es</w>
trans pl
thou gh</w>
sion .</w>
plas ma</w>
per io
patient s.</w>
p sy
ous ly</w>
is o
fir st</w>
comp le
com m
an aly
v entr
ti s
p le
meth yl
ma in
gi ven</w>
d ing</w>
com plic
c yc
be havi
b io
un der
therap y.</w>
si s.</w>
re ,</w>
ou t
inf usion</w>
g e
do se
d es
d ed</w>
an im
P A
week s</w>
ventr ic
pre v
per form
myocardi al</w>
ing s</w>
gra ph
exper im
car b
vas cular</w>
th ree</w>
ro lim
n ec
hi gh</w>
f ind
d rom
c an</w>
3 0</w>
( A
ur ia</w>
ty p
re duction</w>
ot or</w>
me an</w>
ic ot
for e</w>
ex amin
es the
duc e</w>
du e</w>
d -
- old</w>
tim e</w>
pres ent
os ph
m ac
e red</w>
METHOD S:</w>
L -
2 0</w>
ventric ular</w>
ven ous</w>
syn drom
si mil
se ver
resp ecti
pl ace
p it
m it
e pi
d at
bet a
inj ection</w>
im pro
i p
g res
f lu
ect s</w>
cardi o
a v
- 1
v it
u p</w>
ren t</w>
r h
per id
me n</w>
l it
em ia</w>
dise ase</w>
ati c</w>
amph et
E C
A l
the ir</w>
sion ,</w>
s )</w>
r ine</w>
m ark
inv ol
inc idence</w>
hy po
ex t
dise as
bra in</w>
ac id</w>
4 .
( P
we ll</w>
ur al</w>
ter m</w>
st ri
si de
re ver
por t
ph osph
n icot
in iti
high er</w>
fi b
fail ure</w>
er al</w>
di ag
d s</w>
coca ine</w>
ve l</w>
ur ther</w>
syndrom e</w>
suc h</w>
s tim
s co
respecti vel
m us
li k
g ram
ent ly</w>
el ect
do m
chem o
ce ll</w>
b le
ain ed</w>
administ ered</w>
2 0
ve ly</w>
recei ving</w>
ra di
patient s,</w>
in al</w>
im pa
ia .</w>
hy dro
hi st
d ,</w>
c in
c anc
T I
v alu
ra t</w>
p ul
mic e</w>
ia ,</w>
i ther</w>
e lev
d ra
c ap
at e
ar ac
a ff
( C
throm bo
po st
p y
ol ic</w>
norm al
g en</w>
ence ph
dop amine</w>
az ol
at al</w>
R O
0.0 0
ure .</w>
u red</w>
sub j
re b
re as</w>
psy ch
pre vi
is t</w>
h alo
epi le
en z
en ti
dur ation</w>
dra w
de mon
c lo
ati n</w>
H o
4 -
y -
u al</w>
t ot
simil ar</w>
s ing
re ve
re main
om e</w>
it y,</w>
g e</w>
f t</w>
f er
ent al</w>
b ut
ac tion</w>
a y
U N
N a
I t</w>
1 2</w>
year -old</w>
y si
with in</w>
v al
sion s</w>
se qu
ro le</w>
p r
ox id
occur red</w>
mg/k g
m ents</w>
inf arc
in to</w>
drug s</w>
develop ment</w>
at es</w>
ang io
ad di
ab ility</w>
x im
v ol
ran dom
o p
le ar
l as
in ine</w>
e ither</w>
depend ent</w>
c um
be fore</w>
ad ren
a in</w>
Ho wever,</w>
H B
) -
with draw
w ar
per i
no w
low er</w>
dis or
concentr ations</w>
com par
ca use</w>
a d</w>
T o</w>
N A</w>
A T
2 4</w>
( n</w>
( 3
wh ile</w>
ul t</w>
studi ed</w>
si s,</w>
s ul
reve al
pro long
pro gres
perform ed</w>
ox ic
o ver</w>
month s</w>
mode l</w>
l y,</w>
k now
e u
dat a</w>
centr al</w>
cal c
ass ess
an y</w>
CONCLUSION S:</w>
A n
7 .
treatment .</w>
t ing</w>
sympto ms</w>
rolim us</w>
olog ic</w>
o id
meas ured</w>
l in
id ine</w>
elect ro
eff ective</w>
alpha -
al ge
ab s
a ine</w>
a .</w>
a ,</w>
E :</w>
yc in</w>
v ul
uc le
tox ic</w>
sel ective</w>
poten tial</w>
p ol
n er
ho ur
gh t</w>
f em
en h
decreas e</w>
dam age</w>
con cl
chol est
c is
ar mac
K G
A M
1 9
1 -
- term</w>
w o
syst em
s am
reveal ed</w>
p p
ol er
o f
morph ine</w>
m ul
m in</w>
is h
find ings</w>
c reat
RO UN
KG ROUN
B AC
BAC KGROUN
A f
wee k</w>
transpl ant
t est</w>
sp ec
s on
ren ce</w>
o ver
mic e.</w>
m is
k ine
he pat
f urther</w>
er o
en do
des cri
d os
combin ation</w>
co uld</w>
cl on
beta -
bas el
5 .
3 -
10 0</w>
( P</w>
str uc
st at
sing le</w>
ro s
prolong ed</w>
on t
non -
me mor
mal e</w>
li thi
id ne
ic in</w>
ic ally</w>
hepati tis</w>
de t
con vul
az ep
arac ter
a u
BACKGROUN D
6 0</w>
0 -
se t</w>
reb ral</w>
protein uria</w>
pro l
ph ysi
on g</w>
n a
me dic
lo com
increas es</w>
in -induced</w>
i red</w>
hypoten sion</w>
f our</w>
bl ad
ar b
a use</w>
v id
ti n</w>
t em
po si
par tic
k idne
i l</w>
halo perid
g reat
f ar
ev idence</w>
ec ause</w>
differen t</w>
deter min
concentr ation</w>
ch aracter
anim als</w>
ab ol
T w
BACKGROUND :</w>
Af ter</w>
1 5</w>
year s</w>
tis su
tic al</w>
th al
t u
t oler
s y</w>
s af
pl e</w>
ox y
om a</w>
micro gram
ma j
inj ur
i tion</w>
group s</w>
f u
et y</w>
epile p
car cin
at ten
at ory</w>
ain ing</w>
ac h</w>
P ati
9 5%</w>
0.0 5
ur on
th rou
t ak
si x</w>
seiz ures</w>
s ome</w>
s ed</w>
p .
odi um</w>
nit ro
mode l
int rac
ing ,</w>
im port
fem al
f o
dis continu
di st
comm on</w>
co ur
chang e</w>
cell s</w>
am p
a y</w>
S R
% ,</w>
ve ment</w>
tot al</w>
ri am
re pe
re duc
prote in</w>
per ative</w>
ot oxic
mg/ m
li al</w>
l y
intra venous</w>
inj ec
high -
he mo
gen e
g u
flu o
f ac
ex pression</w>
c ess
bra dy
ap pe
ane ous</w>
a ver
Pati ents</w>
4 0</w>
- 1</w>
w om
u lo
typ e</w>
therap eu
th ere</w>
tac hy
t ra
pro duced</w>
place b
placeb o</w>
p ra
p ac
or t
m b
lo c
l ine</w>
k ed</w>
in ary</w>
il d
h um
experim ental</w>
e t</w>
e m</w>
de s</w>
cardi a</w>
basel ine</w>
assess ed</w>
am ide</w>
P )</w>
C A
whe reas</w>
us ,</w>
ter n
s it
re le
on ary</w>
o id</w>
ne g
n ing</w>
min ut
memor y</w>
medi an</w>
m l
le vel</w>
includ ing</w>
great er</w>
glomer ular</w>
en s
d y</w>
co un
blad der</w>
arter y</w>
ant s</w>
anc ed</w>
an s</w>
am in</w>
am eth
Th ere</w>
TI V
O n
w or
vi v
v ast
su ff
s odium</w>
re gi
re cur
re cor
r in</w>
per c
par t
ne uron
mor rh
mechanis ms</w>
m ou
m ic</w>
inhibit or</w>
inf u
i tive</w>
hyperten sion</w>
he morrh
exper i
er y
d ou
chemo therapy</w>
ch ild
cardio vascular</w>
canc er</w>
ca u
bo dy</w>
arter ial</w>
an esthe
an ce
a vi
EC TIV
A d
therapeu tic</w>
result ed</w>
ph armac
p ine</w>
or g
on e
nicot ine</w>
locom otor</w>
iti es</w>
ing .</w>
indic ate</w>
i ly</w>
hepati c</w>
gl ut
g o
em ent</w>
di ff
de press
da ily</w>
con sist
cl ero
as t</w>
antagon ist</w>
am e
a w
O B
OB J
OBJ ECTIV
I I</w>
1 3</w>
1 2
vit amin</w>
v ac
ud e</w>
tiv ity</w>
struc t
st ro
r hy
rhy th
pri or</w>
poten ti
pos sible</w>
os pit
me mb
m ol
it ed</w>
ish ed</w>
im en
im ag
id oc
he m
he al
expos ure</w>
cont rac
co gn
cis pl
ap p
analy sis</w>
am ong</w>
ab l
CONCLUSION :</w>
Al though</w>
1 ).</w>
( S
% ).</w>
withdraw al</w>
vi e
u res
ti co
sur g
ster one</w>
reco very</w>
recept or
rat s,</w>
r it
pi d</w>
perio d</w>
p tion</w>
on set</w>
o st
o graph
mul ti
mo d
maj or</w>
m R
long -term</w>
l or
k g
k e
in son
in duc
in d</w>
id enti
follow ed</w>
follow -
fi ve</w>
examin ed</w>
evalu ated</w>
c it
b il
b en
atri al</w>
A ll</w>
6 .
( 0.
z e</w>
toxic ity.</w>
throu gh</w>
stim ul
st rat
ser i
s us
re d.</w>
mon it
memb ran
m ine</w>
lik e</w>
le ft</w>
l idoc
know n</w>
iz ation</w>
in s</w>
hear ing</w>
h e</w>
frequ ency</w>
er ,</w>
enceph alo
diag no
cor onary</w>
con di
cogn itive</w>
co ll
cal ci
c at
at ro
ap pro
ag ents</w>
ad j
T R
N e
D e
C I
A N
6 -
1 3
- H
+/ -
( -
v ud
um b
u r</w>
ti s.</w>
the sis</w>
sever ity</w>
remain ed</w>
pro duc
previ ously</w>
prev ent
pres ence</w>
pre gn
ob t
nec ro
met abol
medi ated</w>
los s</w>
ll ed</w>
lithi um</w>
is m</w>
inhib ition</w>
i de
hem oly
ha em
e p</w>
disor der
diseas e.</w>
di vid
cyc lo
cy to
cor rel
con ver
at ed.</w>
ang i
al though</w>
al .</w>
ag ain
ac id
Th e
P ro
M A
C om
C h
yl chol
y l</w>
t r
stud y,</w>
sensi tivity</w>
secon d</w>
s ol
s le
ri b
posi tive</w>
path y.</w>
oten s
on d
na use
mechanis m</w>
m g
m ag
includ ed</w>
impa ir
hour s</w>
heal th
fact or</w>
f ul
f ree</w>
dys kine
di rec
creat inine</w>
b in</w>
ati s
an e</w>
amphet am
al ,</w>
ad riam
ab normal
M D
B A
8 .
1 )</w>
wo men</w>
treatment ,</w>
ti l
ti es</w>
the lial</w>
suggest s</w>
st ar
st and
si m
si c</w>
show n</w>
ro w
recept ors</w>
re sist
psych o
prote ren
ph rine</w>
ph eral</w>
p oly
o ch
m m
m en
is ol
investig ated</w>
in o
immun o
ic ep
ic ac
g am
fluo ro
expos ed</w>
ev o
enz ym
ens ity</w>
dou ble
dose -
dop a</w>
dis c
di a
de l
con f
angi otens
ak e</w>
again st</w>
a th
G rou
C a
2 7
2 ,</w>
- treated</w>
( N
( D
x ameth
ure ,</w>
ti z
ti d
stud y.</w>
stat us</w>
st ra
sen s
py ri
pri m
olog y</w>
n umb
n ucle
ma xim
lo l</w>
le u
k ing</w>
infarc tion</w>
import ant</w>
hum an</w>
he mat
gl yc
fi ed</w>
femal e</w>
ev ents</w>
ery th
dys function</w>
dys func
double -
d oc
cor tico
comple te</w>
ch lor
c es</w>
c er
ar ly</w>
ar d</w>
an emia</w>
amphet amine</w>
ami de
abs ence</w>
ab le
OBJECTIV E:</w>
E P
A c
1 1</w>
( T
( 6
whe ther</w>
ver su
versu s</w>
ty -
tic ally</w>
t en</w>
str ated</w>
seiz ure</w>
s hi
s :</w>
ri al</w>
res ult</w>
present ed</w>
pos sib
pl us</w>
p ent
och ond
oc amp
neuro log
me .</w>
m ia</w>
m as
m .</w>
iso proteren
injur y</w>
inf lu
in ic</w>
hyper alge
h ospit
glut am
gener ation</w>
gen ic</w>
g ran
follow- up</w>
f ic
eff icac
determin ed</w>
deter mine</w>
c re
behavi oral</w>
b ac
ar rhyth
an a
ag ent</w>
ac tin</w>
Tw o</w>
M R
M P
6 %</w>
) ;</w>
wit ch
w il
suggest ed</w>
sub st
s o
s ;</w>
s /
s -
rever sible</w>
reg imen
re s</w>
prot ective</w>
pp ocamp
peri pheral</w>
p ot
on e,</w>
n os
mon ary</w>
ment al</w>
me d
mR NA</w>
m ight</w>
l y.</w>
is on</w>
inhibit ors</w>
hi ppocamp
func tional</w>
ev ent
ep iso
control s</w>
cont aining</w>
calci um</w>
azol e</w>
azep ine</w>
ation s.</w>
associ ation</w>
ami vud
ag es</w>
ag e,</w>
activ ation</w>
ab ly</w>
P G
I V</w>
I I
HB V</w>
1 ,</w>
0 %</w>
we igh
valu es</w>
ur inary</w>
un der</w>
tissu e</w>
suff ici
su al</w>
st atis
sp ont
sign s</w>
se d.</w>
s mo
s m
ri c</w>
rele ase</w>
rat ory</w>
ran ge</w>
pi ratory</w>
otoxic ity</w>
ot on
oc icep
mi gra
los por
lo ro
l ym
l ur
inj ected</w>
health y</w>
g row
experi enc
e ly</w>
e ach</w>
diag nos
demon strated</w>
complic ation</w>
com it
c ul
c an
bio p
b ecause</w>
ate ly</w>
arb it
ap o
and /
and/ or</w>
all y,</w>
al ity</w>
al ine</w>
ag ed</w>
ag e.</w>
ac tive</w>
R e
I m
I N
G F
B C
9 .
. )</w>
( p</w>
x i
v s.</w>
use .</w>
u st
tran si
tim es</w>
tic s</w>
t um
t .</w>
t ,</w>
subj ects</w>
stim ulation</w>
seiz ures
secon d
se x
se en</w>
sam e</w>
s ch
respon ses</w>
res ol
r ati
pul monary</w>
pro p
po sto
pi vac
out com
on ic</w>
ol -induced</w>
obt ained</w>
obser v
ob arbit
mit ochond
m m</w>
lym ph
log ra
lit er
liter at
lidoc aine</w>
leu k
inter v
in duction</w>
in duce</w>
ific ation</w>
i or</w>
hydro x
gam ma
for m</w>
f rac
ex ten
evo ked</w>
er .</w>
em b
elev ated</w>
ear ly</w>
e ven</w>
double- bl
do x
differen ces</w>
cyclo phosph
cyc lospor
cont ra
combin ed</w>
chem ical</w>
ch an
chan ne
ce rebral</w>
carb am
c lear
c es
be ing</w>
amin o
administ r
ad v
ab out</w>
T A
T )</w>
On e</w>
E ff
D )</w>
3 ,</w>
1 7
1 6</w>
1 4</w>
y p
y o
vol um
transpl ant</w>
test ed</w>
t rac
syst olic</w>
syst em</w>
syn dro
sle ep</w>
sign ed</w>
sever al</w>
s a
ret ur
respectivel y.</w>
res piratory</w>
pres su
pre dic
place bo
pi lo
os up
on e.</w>
ocy te</w>
numb er</w>
n am
mus c
me tid
me ,</w>
m an</w>
invol ved</w>
initi al</w>
in ergic</w>
i ed</w>
ho wever,</w>
hi sto
he ad
haloperid ol</w>
fe at
eryth ro
er s.</w>
epilep tic</w>
dose .</w>
do g
disc us
def ici
con comit
ce p
ay s</w>
app ear
ap ine</w>
antagon ist
al one</w>
ag ent
aff ected</w>
ab or
ab il
P re
P ark
N o</w>
C on
C O
6 ,</w>
( n
( 5
% .</w>
% ),</w>
y e
wom an</w>
ur ing</w>
ur ac
under ly
underly ing</w>
tri al</w>
test s</w>
tak ing</w>
sympto m
surg er
sup por
su m
str ic
ster oid
spec if
specif ic</w>
second ary</w>
sec re
saf ety</w>
ri ght</w>
ri g
reac tions</w>
re st
re .</w>
ran g
prol actin</w>
pres sive</w>
pr amine</w>
ph ase</w>
path y,</w>
p ur
neg ative</w>
n ot
ment .</w>
ma int
m ut
l amivud
l am
kidne y</w>
inhibit or
immun osup
im medi
il t
i. p.
hyperten sive</w>
g re
g ast
frequ ent</w>
form ation</w>
far in</w>
fact ors</w>
f oc
efficac y</w>
e qu
dy nam
do es</w>
di aly
de ple
day s.</w>
control s.</w>
ci metid
c ros
atri c</w>
as si
ane ur
ana esthe
adren ergic</w>
ad en
T E
S i
R ec
Park inson
H e
2 1</w>
10 -
1 4
( 4
ye ar</w>
y ro
y oun
vi sual</w>
vast atin</w>
tum or</w>
tre m
ter s</w>
tem por
t ub
t ro
stro k
si rolimus</w>
sensi tive</w>
sco pol
ri ll
re vie
pro b
pre treatment</w>
phen y
p ap
ox if
ocardi ograph
o re
neuro pathy</w>
ner ve</w>
m id
lik ely</w>
impro ved</w>
impa ired</w>
i. v
i f</w>
ho l</w>
group s.</w>
glutam ate</w>
gene sis</w>
fu l</w>
es tim
er ing</w>
effect s.</w>
e very</w>
diagno sis</w>
def ic
de si
cour se</w>
con side
clo z
ci r
ca ffe
c ess</w>
bu pivac
b le</w>
atten u
at h</w>
at eral</w>
at e,</w>
anti depress
aneur ys
amin oph
al co
addi tion</w>
ac cum
S )</w>
O f</w>
K 50
H C
F K50
D O
C R
1 8
1 7</w>
1 ),</w>
tion s.</w>
ti s,</w>
thrombo tic</w>
te d.</w>
t -
system ic</w>
sul f
sub sequ
stri at
st ate</w>
sp inal</w>
si a.</w>
sho w</w>
ser oton
sal ine</w>
s witch
ri pt
ran ial</w>
pro duce</w>
pro ce
pra z
p u
or t</w>
on i
ol e</w>
of ten</w>
o sterone</w>
ne w</w>
ne ed</w>
n ess</w>
multi ple</w>
mou se</w>
mitochond rial</w>
mg/kg )</w>
mg/ d
lit ax
le sions</w>
l arg
it e</w>
is tic</w>
io d
inter sti
inhibit ed</w>
influ ence</w>
inf lam
in divid
im plic
i g
high- dose</w>
hemoly tic</w>
he par
glyc er
fib rill
fail ure.</w>
f low</w>
enh anced</w>
endo thelial</w>
enceph al
ecti vely</w>
e ll
do min
differen ce</w>
de ath</w>
cur rent</w>
contra st
com mon
cholest er
chol inergic</w>
cau ses</w>
calc ification</w>
c T
cT n
b rom
b ed</w>
au to
ati vely</w>
ar th
ap pa
an ic</w>
adj ust
ad e</w>
a thi
W he
T reat
R D
Parkinson 's</w>
P h
A D
5 5
5 ,</w>
2 5</w>
. ,</w>
z ed</w>
ylchol ine</w>
we ight</w>
vari ous</w>
ut aneous</w>
us ers</w>
ur ine</w>
un d
the tic</w>
tachy cardia</w>
t ly</w>
stand ard</w>
st res
si ze</w>
se ven</w>
se g
se d
se .</w>
ri tis</w>
repor ts</w>
reac tion</w>
re comm
pres cri
pre -
pilo car
par tial</w>
ocy to
oc c
no vel</w>
month s.</w>
mis sion</w>
minut es</w>
ma .</w>
m otor</w>
le ad
k in
ist ar</w>
investig ate</w>
intersti tial</w>
indic ating</w>
in sti
imag ing</w>
ic ill
i m</w>
head ac
group .</w>
glomer ul
gl y
experienc ed</w>
enzym e</w>
ent an
en e</w>
en d</w>
ech ocardiograph
e pa
e di
drug .</w>
direc t</w>
contro lled</w>
cont r
complic ations</w>
co -
cispl atin</w>
c h</w>
ay ed</w>
aver age</w>
as e,</w>
ap ri
am oun
al logra
ac hi
a sis</w>
a m</w>
W istar</w>
O ur</w>
I C
D i
D F
D -
C lin
A n</w>
A L
7 -
3 4
2 )</w>
( p
( B
y s</w>
y n
volum e</w>
ver ap
ve ,</w>
um ,</w>
u tive</w>
u s.</w>
u ally</w>
therap y,</w>
ther os
theros clero
the y</w>
th ir
th en</w>
tac rolimus</w>
t es</w>
suggest ing</w>
st on
st e
shi p</w>
s cor
s ),</w>
rever sed</w>
ref o
refo re,</w>
re n</w>
random ized</w>
progres sive</w>
pro v
pro f
posto perative</w>
pl ate
plate le
phen yl
phen obarbit
ph yl
pac litax
p id
or ub
on s</w>
nause a</w>
n or
model s</w>
mo der
min im
micro angio
li f
lev o
l abor
is chem
iod ar
ilt ration</w>
id ity</w>
id al</w>
hyper activity</w>
grow th</w>
glo bin</w>
f ron
ext rac
ex pl
epa m</w>
en ge</w>
e l</w>
di et</w>
descri be</w>
conside red</w>
con sum
comple te
clon idine</w>
child ren</w>
channe l</w>
carcin o
carbam azepine</w>
c ys
be ll
b ar
av oid
ation ship</w>
at ed
an alge
amin ergic</w>
a de
N O
Grou p</w>
D 2</w>
C l
8 0
2 5
(1 0</w>
( V
w ho
who m</w>
vi ral</w>
ve red</w>
ve d.</w>
ve .</w>
val pro
ur b
ud ed</w>
